| Vaccine Platform | Type of Vaccine
and Immunogen | Developer
(Name of Vaccine) | Dose Schedule
and Administration | Phase* | Excipients† |
|---|
| RNA-based vaccine | - mRNA encoding spike protein (30 μg)
| BioNTech–Pfizer
(BNT162b2) | - Two doses (day 0, day 21)
- Intramuscular
| Post-EUA | 0.43 mg ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), 0.05 mg
2[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, 0.09 mg 1,2-distearoyl-sn-glycero-3-phosphocholine, and 0.2 mg cholesterol, 0.01 mg potassium chloride, 0.01 mg monobasic potassium phosphate, 0.36 mg sodium chloride, 0.07 mg dibasic sodium phosphate dihydrate, and 6 mg sucrose. The diluent (0.9% sodium chloride Injection) contributes an additional 2.16 mg sodium chloride per dose |
| RNA-based vaccine | - mRNA encoding spike protein (100 μg)
| Moderna
(mRNA-1273) | - Two doses (day 0, day 28)
- Intramuscular
| Post-EUA | Lipids (SM-102; 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 [PEG 2000-DMG]; cholesterol; and 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC]), tromethamine, tromethamine hydrochloride, acetic acid, sodium acetate, and sucrose |
Adenovirus vector
(nonreplicating) | - ChAdOx1-Sn Cov-19
- Nonreplicating chimpanzee AdV5 expressing spike protein
| AstraZeneca and University of Oxford
(AZD1222) | - One (day 0) or two (day 0, day 28) doses
- Intramuscular
| Phase 3 | 10 mM histidine, 7.5% (w/v) sucrose,
35 mM sodium chloride, 1 mM magnesium
chloride, 0.1% (w/v) polysorbate 80,
0.1 mM edetate disodium, 0.5% (w/v)
ethanol, at pH 6.6 |
Adenovirus vector
(nonreplicating) | - Ad26.COV2.S
- Adenovirus 26 vectored vaccine using AdVac and PER.C6 technology
| Janssen | - One (day 0) or two (day 0, day 56) doses
- Intramuscular
| Phase 3 | Sodium chloride, citric acid monohydrate, polysorbate 80, 2 hydroxypropyl-B-cyclodextrin (HBCD), ethanol (absolute), sodium hydroxide |
| Protein subunit | - Full-length recombinant SARS-CoV-2 glycoprotein nanoparticle with Matrix M adjuvant
- Spike prefusion protein
| Novavax | - Two doses (day 0, day 21)
- Intramuscular
| Phase 3 | Matrix M1 adjuvant
Full-length spike protein formulated in polysorbate 80 detergent and Matrix M1 adjuvant |
| Protein subunit | - SARS-CoV-2 vaccine formulation with adjuvant (S-protein) (Baculovirus production)
- Spike protein
| Sanofi Pasteur and GSK | - Two doses (day 0, day 21)
- Intramuscular
| Phase 1–2 | Sodium phosphate monobasic monohydrate, sodium phosphate dibasic, sodium chloride polysorbate 20, disodium hydrogen phosphate, potassium dihydrogen phosphate, potassium chloride |
Phase information was current as of December 21, 2020. In all cases, the placebo was normal saline.
† Bold entries are excipients potentially related to vaccine reaction that may be cross-reactive to other excipients (e.g., PEG 2000 and polysorbate 80). SM-102, a component of the Moderna vaccine, is a proprietary ionizable lipid. |
